Pluri Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluri Inc. on October 16, 2025, regarding events occurring on October 15, 2025. The company is incorporated in Nevada and operates from Haifa, Israel. The filing addresses Item 5.02 concerning the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments rather than financial performance results.
Material Changes
The Board of Directors approved a new equity grant package for Chief Executive Officer Yaky Yanay on October 15, 2025, recognizing performance objectives achieved during fiscal year 2025. The immediate grant includes:
- 39,050 fully vested Restricted Stock Units (RSUs).
- Stock options to purchase 39,050 common shares, fully vested and exercisable for three years at an exercise price of $5.00 per share.
Additionally, the Board approved a contingent future grant, dependent on achieving specific objectives by December 31, 2025. If awarded, this future grant will consist of:
- 9,266 RSUs.
- Stock options to purchase 9,266 common shares, exercisable for three years at an exercise price of $5.00 per share.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on market outlook, or discussion of risks and contingencies beyond the standard disclosure of the compensation terms. The unusual item noted is the specific timing and structure of the CEO's equity award tied to fiscal year 2025 performance.
Investor Verification Checklist
- Verify the exact vesting conditions and performance metrics required for the contingent grant of 9,266 RSUs and options.
- Confirm the total number of outstanding shares and the dilution impact of the 78,100 total potential shares (immediate and contingent) granted to the CEO.
- Review the company's stock price relative to the $5.00 exercise price to assess the immediate value of the vested options.
- Check subsequent filings to confirm if the December 31, 2025 performance objectives were met and the contingent awards were issued.